The Second Affiliated Hospital of Fujian Medical University, No. 34 Zhongshan North Road, Licheng District, Quanzhou, 362000, Fujian, China.
Sleep Breath. 2021 Mar;25(1):1-8. doi: 10.1007/s11325-020-02078-1. Epub 2020 Apr 24.
It remains inconclusive whether continuous positive airway pressure (CPAP) therapy can significantly reduce subcutaneous adipose tissue (SAT) in patients with obstructive sleep apnea (OSA). This meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the impact of CPAP treatment on SAT in patients with OSA.
We searched Pubmed, Cochrane, Web of Science, and Embase for RCTs, which investigated the effectiveness of CPAP treatment in reducing SAT among patients with OSA. Following the PRISMA guidelines, we extracted information on the study and patient characteristics, and pre- and post-CPAP measures of SAT. We then calculated the overall effects using the standardized mean difference (SMD) with a 95% confidence interval (CI).
A total of 5 RCTs (comprising 153 patients) met inclusion criteria for the meta-analysis. We found that the SAT did not change before and after CPAP treatment in patients with OSA (SMD = - 0.02, 95% CI - 0.25 to 0.2, z = 0.19, p = 0.85). Subgroup analyses indicated that the outcome was not affected by age, CPAP therapy duration, baseline body mass index, and measure utilized.
This meta-analysis of RCTs suggests that CPAP therapy does not significantly decrease the level of SAT among patients with OSA. Further large-scale, and high-quality randomized controlled trials are needed to better address this issue.
持续气道正压通气（CPAP）治疗是否能显著减少阻塞性睡眠呼吸暂停（OSA）患者的皮下脂肪组织（SAT）尚不清楚。本荟萃分析旨在评估 CPAP 治疗对 OSA 患者 SAT 的影响。
我们检索了 Pubmed、Cochrane、Web of Science 和 Embase 中的 RCTs，这些 RCT 调查了 CPAP 治疗在降低 OSA 患者 SAT 中的有效性。根据 PRISMA 指南，我们提取了关于研究和患者特征以及 CPAP 治疗前后 SAT 测量的信息。然后，我们使用标准化均数差（SMD）和 95%置信区间（CI）计算了总体效果。
共有 5 项 RCT（包含 153 名患者）符合荟萃分析的纳入标准。我们发现，CPAP 治疗前后 OSA 患者的 SAT 没有变化（SMD = - 0.02，95%CI - 0.25 至 0.2，z = 0.19，p = 0.85）。亚组分析表明，结局不受年龄、CPAP 治疗持续时间、基线 BMI 和测量方法的影响。
这项 RCT 的荟萃分析表明，CPAP 治疗并不能显著降低 OSA 患者的 SAT 水平。需要进一步的大规模、高质量的随机对照试验来更好地解决这个问题。
